Etanercept is a tumor necrosis factor alpha (TNF-α) antagonist with anti-inflammatory effects. It is used in the treatment of dermatologic and rheumatologic diseases such as rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. However, etanercept has various cutaneous and systemic side effects. Herein, we report a case of generalized pustular eruption due to etanercept therapy in an ankylosing spondylitis patient and review pustular diseases.
tanercept is the first tumor necrosis factor-alfa (TNF-α) antagonist obtained from human protein. Etanercept is an FDA approved drug was firstly used in the treatment of rheumatoid arthritis (RA) in the year 1998. It has been used in the treatment of polyarticular juvenile rhematoid arthritis, psoriatic arthritis, anxylosing spondylitis (AS) and moderate-severe chronic plaque psoriasis with FDA approval [1] . Pustular eruption due to etanercept is rare. Pustular eruption commonly seen with antibiotics, corticosteroids, antiepileptic agents, anthistaminics, and nonsteroidal antiinflammatory drugs [2] . Herein, we report a case of pustular eruption developed due to etanercept therapy in an AS patient.
CASE REpoRT
A 45-year-old male with the diagnosis of AS, consulted to our outpatient clinic with itching and pustular eruption on his palms, soles, trunk, and back. His complaints had developed after the first course of etanercept treatment. The skin rash had started on the back 1.5 months ago and gradually had increased after the second and third courses of etanercept therapy, and finally had spread to the palms and soles. The medical history was unremarkable. In the family history, mother of the patient had diabetes mellitus and hypertension, his father had coronary artery disease. The patient was generally healthy and had no fever. Laboratory tests were unremarkable. On dermatological examination, multiple erythematous pustules and papules were observed on the both palmar and plantar regions, trunk, and back ( Figures  1-3 ). There was no bacterial growth on the culture media taken from the pustular lesion.
Histopathological examination revealed intraepidermal infiltration of neutrophils and eosinophils, and also inflammatory cells infiltration in the papillary dermis ( Figure 3) . We diagnosed the patient as pustular drug eruption with the histopathological and clinical findings. After withdrawal of the etanercept therapy, the skin lesions cleared within 3 weeks. Low-dose oral methylprednisolone, oral antihistaminic, and topical steroid therapies were started. We did not observe any new skin lesion during the follow-up of a year.
DiSCuSSion
Pustular drug eruptions are rarely seen forms of drug reactions. In diagnosis of pustular drug eruption, presence of suspicious drug use history, histopathological examination, and rule out of other pustular dermatoses are important. The most frequently responsible drugs are antibiotics, antifungal, antituberculostatic, and antiepileptic drugs. Pustular drug eruption due to TNF-α antagonists have been reported previously [3, 4] .
TNF-α antagonists have been successfully used in the treatment of several chronic autoimmune and inflammatory diseases. Among these agents, etanercept is a recombinant TNF-α receptor (TNFR) fusion protein and constitutes of two extracellular components bound to Fc fragment of human IgG. It competitively inhibits the interaction of circulatory TNF-α with cell surface receptors [5] . It is an effective agent in the treatment of moderately severe chronic psoriasis, psoriatic arthritis, RA, juvenile rheumatoid arthritis, and AS. Although it has been safely used in many diseases, drug-induced adverse effects have been observed [6] .
Etanercept has systemic adverse effects involving
North Clin Istanbul -NCI 232 reviewed and 42.9% of 184 cases on anti-TNF-α had pustular lesions as adverse effects [10] .
Other cutaneous adverse effects due to etenarcept are eczematous eruptions, cutaneous lymphoma, herpes simplex infection, bacterial infections, lichenoid eruptions, erythema multiforme, lupus erythematosus, and acute generalized exanthematous pustulosis. Among 153 patients reported as case reports, psoriasis and its subtypes (n=38), skin infections (n=31), malignancies (n=15), lupus and related skin manifestations (n=19), and other non-specific skin diseases (n=35) have been found associated with adverse effects due to etanercept that nonspecific skin rash was the most frequently detected finding [7] . In only one case, generalized maculopapular eruption have been reported [11] . In a study, an increase in the frequency of pustular dermatitis has been reported during anti-TNF-α therapy. This study revealed that especially TNF-α blockage increased the release of interferon-alfa (IFN-α) and the frequency of pustular dermatitis and psoriasis [12] . In our case, we observed erythematous pustules and papules on both palmar and plantar regions, ventral side of trunk, and back as adverse effects of etanercept treatment.
In the differential diagnosis of pustular eruption, generalized pustular psoriasis, Reiter syndrome, subcorneal pustular dermatosis, acute generalized exanthematous pustulosis (AGEP), acneiform drug eruptions, folliculitis, eosinophilic folliculitis, activation of latent infections such as tuberculosis, increase the frequency of demyelinizating diseases, and development of malignancy [7] . In addition, cutaneous adverse effects of etanercept are not rare. Cutaneous reactions have been reported in nearly 65 cases [7] . The most frequently reported cutaneous adverse effect of etanercept is injection site reaction. This reaction is characterized by eythema, itching, pain, and edema on the injection site [7, 8] . In our case, we did not observe such a reaction during the etanercept therapy.
Etanercept induces various cutaneous symptoms that exacerbation of psoriasis symptoms is one of the adverse effects. It has been recommended that these symptoms should be treated as psoriasis and another TNF-α antagonist should be started in resistant cases [6] . However, in a case series reported in the literature, in two cases treated with anti-TNF-α, upon development of psoriatic symptoms, another anti-TNF-α agent also induced psoriatic manifestations [9] . In the literature, apart from etanercept, exacerbation of psoriatic symptoms has been observed also with infliximab and adalimubab. In a study performed by Joyau et al., pustular lesions, especially on palmoplantar regions, have been observed in the patients with AS, Crohn' s disease, RA, plaque psoriasis on anti-TNF-α therapy with the frequency of 33%. Of these patients, 1.7% had palmoplantar pustular psoriasis. In nearly half of the patients, these side effects developed secondary to infliximab. In the same study literature had been palmoplantar pustulosis, SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis), handfoot-and-mouth disease, and viral diseases such as varicella should be considered [3, 13, 14, 15, 16] . Clinical and histopathological examinations are helpful in the differential diagnosis (Table 1) . Histopathologically, acanthosis and psoriatic changes at dermoepidermal junction are seen in pustular psoriasis, whereas massive edema in the superficial dermis, perivascular eosinophilic infiltration, and keratinocytic necrosis are seen in AGEP [8] . Histopathological examination of our patient revealed intraepidermal cells infiltration involving neutrophils and eosinophils and also inflammatory cells infiltration in the papillary dermis. We diagnosed the patient as pustular drug eruption with these clinical and histopathological findings.
In conclusion, cutaneous side effects can be seen with etanercept therapy and the therapy should be discontinued if these adverse effects develop. Adverse effects regress with cessation of etanercept therapy in most cases, however, cutaneous symptoms should be treated in some cases [7, 8] . We observed marked improvement in the skin lesions after cessation of etanercept therapy. In addition, we also started therapies for cutaneous symptoms.
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